Answer to Reviewers. Merelli et al 2011 Reviewer 1 1. The title was changed to: Experimental evidences of the potential use of Erythropoietin by intranasal administration as neuroprotective agent in cerebral hypoxia. 2. The concepts of anoxia, hypoxia and oxygen deprivation were clarified in the manuscript. 3. This mini-review is focused only in the experimental data related to intranasal administration of Epo in animal models of stroke as potential neuroprotective agent. 4. The figure 1 was modified according to reviewer corrections. See file attached. 5. The passage on page 4 was changed to: The neuroprotective efficacy of Epo or its analogues have been evaluated in several experimental models of brain hypoxia. Middle cerebral artery occlusion (MCAO) model resulted to be the most commonly model used. Fourteen MCAO studies showed a great disparity in different variables such as duration of occlusion intervals as well as the doses, routes and/or the administration timing of Epo or its analogues. However, the results of all these studies suggest that when administered after the onset of ischemia, Epo reduced infarct size and improved neurobehavioral deficits significantly, as showed in our experiments (18). These effects were associated with both higher doses and earlier administration of the hormone after experimental stroke initiation (24). 6. The typographical errors were corrected. Reviewer 2 1. The title was changed to: Experimental evidences of the potential use of Erythropoietin by intranasal administration as neuroprotective agent in cerebral hypoxia. 2. The typographical errors were corrected. Page 1 of 11